Armstrong Fleming & Moore Inc trimmed its position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 16.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,177 shares of the medical research company’s stock after selling 418 shares during the quarter. Armstrong Fleming & Moore Inc’s holdings in IQVIA were worth $428,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of IQV. Pine Valley Investments Ltd Liability Co boosted its position in shares of IQVIA by 62.3% during the 4th quarter. Pine Valley Investments Ltd Liability Co now owns 15,392 shares of the medical research company’s stock valued at $3,025,000 after acquiring an additional 5,911 shares during the last quarter. Edge Capital Group LLC lifted its position in IQVIA by 622.7% during the fourth quarter. Edge Capital Group LLC now owns 13,096 shares of the medical research company’s stock valued at $2,573,000 after purchasing an additional 11,284 shares during the last quarter. South Dakota Investment Council bought a new stake in shares of IQVIA during the 4th quarter worth $2,462,000. Howard Capital Management Inc. increased its stake in IQVIA by 4.9% in the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock valued at $225,000 after acquiring an additional 54 shares during the last quarter. Finally, Abound Financial LLC purchased a new stake in IQVIA during the fourth quarter valued at about $512,000. Institutional investors own 89.62% of the company’s stock.
Insider Buying and Selling at IQVIA
In other news, Director John G. Danhakl bought 1,275 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now owns 1,275 shares in the company, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders own 1.60% of the company’s stock.
Analyst Upgrades and Downgrades
View Our Latest Stock Analysis on IQV
IQVIA Trading Down 1.9 %
NYSE IQV opened at $190.98 on Wednesday. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The stock’s 50 day moving average is $199.41 and its 200 day moving average is $215.63. The firm has a market capitalization of $33.63 billion, a PE ratio of 25.46, a P/E/G ratio of 1.99 and a beta of 1.48. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.
IQVIA (NYSE:IQV – Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.
IQVIA Company Profile
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
- Five stocks we like better than IQVIA
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Tempus AI Is a Buy, If You Can Handle the Volatility
- Growth Stocks: What They Are, What They Are Not
- Massive Buybacks: 3 Stocks Returning Big Cash to Shareholders
- Investing In Automotive Stocks
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.